Viewing Study NCT06360250


Ignite Creation Date: 2025-12-24 @ 4:48 PM
Ignite Modification Date: 2025-12-28 @ 6:00 AM
Study NCT ID: NCT06360250
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-04-11
First Post: 2024-04-07
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation
Sponsor: Changchun BCHT Biotechnology Co.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module